Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.

Clinical colorectal cancer - 1 Jun 2016

Cohen Stacey A, Wu Chen, Yu Ming, Gourgioti Georgia, Wirtz Ralph, Raptou Georgia, Gkakou Chryssa, Kotoula Vassiliki, Pentheroudakis George, Papaxoinis George, Karavasilis Vasilios, Pectasides Dimitrios, Kalogeras Konstantine T, Fountzilas George, Grady William M

Abstract excerpt

BACKGROUND: The CpG island methylator phenotype (CIMP) is a promising biomarker for irinotecan/5-fluorouracil/leucovorin chemotherapy for stage III colon cancer. In the present study, we evaluated whether CIMP is a prognostic biomarker for standard-of-care oxaliplatin-based adjuvant therapy. MATERIALS AND METHODS: The HE6C/05 trial randomized 441 patients with stage II-III colorectal adenocarcinoma to adjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CpG Islands

Share to Deoxycytidine

Share to Fluorouracil

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Open in PubMed Open full text

Identifiers

PMID: 26702772
DOI: 10.1016/j.clcc.2015.10.005
PMCID: PMC4864501

Genes

BRAF
IGF2
NEUROG1
RUNX3
SOCS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.PMID 26702772Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Semantic proximity Read ↗

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.Semantic proximity Read ↗

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.Semantic proximity Read ↗

Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.Semantic proximity Read ↗

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.Semantic proximity Read ↗

The role of the CpG island methylator phenotype on survival outcome in colon cancer.Semantic proximity Read ↗

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.Semantic proximity Read ↗

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Semantic proximity Read ↗

CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.Semantic proximity Read ↗

The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.